173 related articles for article (PubMed ID: 37296217)
1. Improved on-treatment fibrosis-4 during antiviral therapy and lower hepatocellular carcinoma risk in cirrhotic patients with hepatitis B.
Oh JH; Park Y; Goh MJ; Sinn DH; Ahn SB; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
Sci Rep; 2023 Jun; 13(1):9443. PubMed ID: 37296217
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
3. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
4. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.
Kim EJ; Yeon JE; Kwon OS; Lee HN; Shin SK; Kang SH; Byun KS; Kim JH; Kwon SY; Suh SJ; Yim HJ; Kim YS; Kim JH
Dig Dis Sci; 2017 Mar; 62(3):808-816. PubMed ID: 28035553
[TBL] [Abstract][Full Text] [Related]
5. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase.
Seong G; Sinn DH; Kang W; Gwak GY; Choi MS; Lee JH; Koh KC; Woon Paik S; Paik YH
Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):69-75. PubMed ID: 32925504
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive serum markers for predicting significant liver histopathology in HBeAg-negative chronic HBV-infected patients with normal alanine aminotransferase.
Gao Y; Wang M; Liu X
Microbiol Spectr; 2024 Apr; 12(4):e0394123. PubMed ID: 38426768
[TBL] [Abstract][Full Text] [Related]
7. Management of chronic hepatitis B.
Wilt TJ; Shamliyan T; Shaukat A; Taylor BC; MacDonald R; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL
Evid Rep Technol Assess (Full Rep); 2008 Oct; (174):1-671. PubMed ID: 19408969
[TBL] [Abstract][Full Text] [Related]
8. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis.
Shin SK; Yim HJ; Kim JH; Lee CU; Yeon JE; Suh SJ; Jung YK; Kim YS; Kim JH; Kwon OS
Gut Liver; 2021 May; 15(3):430-439. PubMed ID: 33115966
[TBL] [Abstract][Full Text] [Related]
9. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
Jang H; Yoon JS; Park SY; Lee HA; Jang MJ; Kim SU; Sinn DH; Seo YS; Kim HY; Kim SE; Jun DW; Yoon EL; Sohn JH; Ahn SB; Shim JJ; Jeong SW; Cho YK; Kim HS; Nam JY; Lee YB; Kim YJ; Yoon JH; Zoulim F; Lampertico P; Dalekos GN; Idilman R; Sypsa V; Berg T; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Janssen H; Papatheodoridis GV; Lee JH
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1343-1353.e16. PubMed ID: 34500103
[TBL] [Abstract][Full Text] [Related]
10. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract][Full Text] [Related]
11. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
Choi J; Kim GA; Han S; Lim YS
Am J Gastroenterol; 2020 Mar; 115(3):406-414. PubMed ID: 31895708
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
[TBL] [Abstract][Full Text] [Related]
13. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
14. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis.
Jeng WJ; Chien RN; Chen YC; Lin CL; Wu CY; Liu YC; Peng CW; Su CW; Hsu CE; Liaw YF
Hepatology; 2024 Mar; 79(3):690-703. PubMed ID: 37625144
[TBL] [Abstract][Full Text] [Related]
17. [Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study].
Zhou Y; Hu C; Yuan G; Liu J; Ren Y; Tang C; Yang S; Dai L; Li Y; Yang D
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):633-640. PubMed ID: 31270040
[TBL] [Abstract][Full Text] [Related]
18. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
Chang X; Li Y; Sun C; Li X; Du W; Shang Q; Song L; Long Q; Li Q; Liu H; Wang J; Yu Z; Li J; Xiao G; Li L; Chen L; Tan L; Chen Y; Yang Y
J Gastroenterol; 2023 May; 58(5):481-493. PubMed ID: 36928343
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
Yuan Y; Iloeje UH; Hay J; Saab S
J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
[TBL] [Abstract][Full Text] [Related]
20. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H
J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
